LaNova Medicines' LM-101 IND Submission is Accepted by China NMPA
-
2022-09-05
-
Share:
SHANGHAI, September 5, 2022 – LaNova Medicines announced that the investigational new drug (IND) application of LM-101 has been accepted by the National Medical Products Administration (NMPA). Previously, the project was approved by the US Food and Drug Administration (FDA) in August 2022 to conduct clinical trials in the United States.